1.26

1.56% -0.02

After Hours: 1.29 0.03 +2.38%

Coherus Biosciences Inc (CHRS)

Overview News Price History Option Chain Financials Why CHRS Down? Discussions Forecast

Coherus Biosciences Inc stock is traded at $1.26, with a volume of 3.27M. It is down -1.56% in the last 24 hours and up +60.71% over the past month. Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

Previous Close:

$1.28

Open:

$1.3

24h Volume:

3.27M

Relative Volume:

1.16

Market Cap:

$145.74M

Revenue:

$257.24M

Net Income/Loss:

$-237.89M

P/E Ratio:

-0.3795

EPS:

-3.32

Net Cash Flow:

$-175.17M

1W Performance:

+14.55%

1M Performance:

+60.71%

6M Performance:

-34.03%

1Y Performance:

-35.05%

1-Day Range:

$1.23

$1.35

1-Week Range:

$1.01

$1.39

52-Week Range:

$0.6603

$3.70

Coherus Biosciences Inc Stock (CHRS) Company Profile

Name

Coherus Biosciences Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

(650) 649-3530

Address

C/O DENNIS M. LANFEAR, REDWOOD CITY, CA

Employee

235

Twitter

@coherus_bio

Next Earnings Date

2024-11-06

Latest SEC Filings

CHRS's Discussions on Twitter

Compare CHRS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CHRS Coherus Biosciences Inc	1.26	145.74M	257.24M	-237.89M	-175.17M	-3.32
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Coherus Biosciences Inc Stock (CHRS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-16-24	Downgrade	UBS	Buy → Neutral
Nov-17-23	Initiated	Robert W. Baird	Outperform
Nov-08-23	Downgrade	Maxim Group	Buy → Hold
Jul-24-23	Initiated	Citigroup	Buy
May-01-23	Initiated	Truist	Buy
Mar-28-23	Upgrade	UBS	Neutral → Buy
Jun-14-22	Initiated	UBS	Neutral
Mar-07-22	Downgrade	JP Morgan	Overweight → Neutral
Jul-16-20	Initiated	BofA Securities	Neutral
Apr-17-20	Initiated	SunTrust	Buy
Aug-13-19	Initiated	Mizuho	Buy
Aug-02-19	Reiterated	H.C. Wainwright	Buy
Aug-02-19	Reiterated	Maxim Group	Buy
Jun-11-19	Initiated	Barclays	Overweight
May-07-19	Initiated	H.C. Wainwright	Buy
Aug-28-18	Initiated	H.C. Wainwright	Buy
Mar-09-18	Reiterated	Maxim Group	Buy
Aug-08-17	Reiterated	JP Morgan	Overweight
Jun-13-17	Reiterated	Maxim Group	Buy
May-05-17	Initiated	BMO Capital Markets	Outperform
Oct-19-16	Initiated	Robert W. Baird	Outperform
Sep-07-16	Initiated	Maxim Group	Buy
Jul-27-16	Initiated	Citigroup	Buy
Jan-20-16	Initiated	Credit Suisse	Outperform

View All

Coherus Biosciences Inc Stock (CHRS) Latest News

Nov 27, 2024

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference - Marketscreener.com

Nov 27, 2024

Coherus BioSciences to Present at Citi Healthcare Conference's Oncology Panel | CHRS Stock News - StockTitan

Nov 27, 2024

Nov 23, 2024